Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said https://t.co/tBXk9e6A5O
— Reuters (@Reuters) September 4, 2024
Categories